表紙
市場調査レポート

英国の注射剤市場の将来展望

UK Injectables Market Outlook to 2017

発行 RNCOS E-Services Pvt. Ltd. 商品コード 281914
出版日 ページ情報 英文 45 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
英国の注射剤市場の将来展望 UK Injectables Market Outlook to 2017
出版日: 2013年09月13日 ページ情報: 英文 45 Pages
概要

近年の医薬品市場の不振にも関わらず、英国の注射剤市場は順調に成長しています。技術革新や巨額の投資などに伴い、注射剤の市場機会は今後さらに拡大していくものと思われます。2012〜2017年の年平均(CAGR)成長率は約4.5%と予測されています。

当レポートでは、英国の注射薬市場について分析し、市場の現状や促進・阻害要因、市場動向の見通し(今後5年間の予測値)、分野別の詳細動向、規制環境の変化、主要企業のプロファイルなどを調査して、その結果を概略以下の構成でお届けします。

第1章 アナリストの見解

第2章 分析手法

第3章 英国の注射剤市場の将来展望(今後5年間分)

  • 現在・将来の市場の分析
    • 主要な注射剤(上位10種)の市場動向
    • 主要な治療分野(上位10種)の市場動向
    • 主要企業

第4章 市場の促進要因と課題

  • 市場促進要因
  • 市場の課題

第5章 規制環境

第6章 競争環境

  • Novo Nordisk
    • 事業概要
    • 主な注射剤の売上高
    • 強みと弱み
    • 近年の動向
  • Sanofi
    • 事業概要
    • 主な注射剤の売上高
    • 強みと弱み
    • 近年の動向
  • Eli Lily & Co.
    • 事業概要
    • 主な注射剤の売上高
    • 強みと弱み
  • Pfizer
    • 事業概要
    • 主な注射剤の売上高
    • 強みと弱み
    • 近年の動向
  • Abbott Laboratories
    • 事業概要
    • 主な注射剤の売上高
    • 強みと弱み
    • 近年の動向
  • 武田薬品工業
    • 事業概要
    • 主な注射剤の売上高
    • 強みと弱み
    • 近年の動向

図表一覧

目次

Injectables occupy a considerable prominence in UK irrespective of diminishing growth in the pharmaceutical market for 2-3 years. The advancements in technology up-gradation and investments have provided immense growth opportunities for injectables to emerge in the UK's pharmaceutical industry in recent years. According to RNCOS' research report, "UK Injectables Market Outlook to 2017", the market is anticipated to grow at a CAGR of approximately 4.5% during 2012-2017. The increasing need of injectables for diseases like diabetes, infectious diseases and arthritis is primarily driving this market.

The said report is a study of the UK injectable market in terms of major therapeutic areas. It covers the historical sales trend of injectables for categories such as Diabetes, Vaccines, Sex Hormones & Antagonist in Malign Disease, Anticoagulants & Protamine, Hypothalamic & Pituitary Hormones, Rheumatic Diseases & Gout, etc. Not only this, the report also provides the sales trend of the top 10 injectable drugs in the UK market along with a rational analysis.

Certain pharmaceutical firms in UK's injectable market have established their foothold given the diverse and innovative product offerings. Several small pharma majors too have been aggressively competing with big pharmaceutical players in order to establish themselves in the market. The report highlights a detailed comparison of the market shares of different players in the injectables market.

The study provides an insight about the competitive landscape, which includes business profiling and a strength-weakness analysis of top pharmaceutical players in the UK injectable business. There's also a coverage of the detailed analysis of their top injectable drugs in terms of revenue.

A lot of investment is being done in research and development of injectables in order to improve their medical outcomes. Here it is worth mentioning that even the country's government has significantly contributed towards the development of innovative medicines.

Moreover, the Government has shifted its focus towards cost effective drug treatments by fixing up the drug prices as per their clinical value. In addition, there are a set of regulations that support the injectable drug business in the country. In this context, various regulatory processes such as drug licensing, marketing/ promotion, pricing etc. have been comprehensively covered in the report. In a nutshell, the report covers every aspect of UK injectables which will help the industry players to take strategic decisions.

Table of Contents

1. Analyst View

2. Research Methodology

3. UK Injectables Market Outlook to 2017

  • 3.1 Current and Future Market Analysis
    • 3.1.1 By Top 10 Injectables
    • 3.1.2 By Top 10 Therapeutics
    • 3.1.3 By Major Players

4. Drivers and Challenges

  • 4.1 Drivers
  • 4.2 Challenges

5. Regulatory Environment

6. Competitive Landscape

  • 6.1 Novo Nordisk
    • 6.1.1 Business Overview
    • 6.1.2 Key Injectable Sales
    • 6.1.3 Strengths and Weaknesses
    • 6.1.4 Recent Developments
  • 6.2 Sanofi
    • 6.2.1 Business Overview
    • 6.2.2 Key Injectable Sales
    • 6.2.3 Strengths and Weaknesses
    • 6.2.4 Recent Developments
  • 6.3 Eli Lily & Co.
    • 6.3.1 Business Overview
    • 6.3.2 Key Injectable Sales
    • 6.3.3 Strengths and Weaknesses
  • 6.4 Pfizer
    • 6.4.1 Business Overview
    • 6.4.2 Key Injectable Sales
    • 6.4.3 Strengths and Weaknesses
    • 6.4.4 Recent Developments
  • 6.5 Abbott Laboratories
    • 6.5.1 Business Overview
    • 6.5.2 Key Injectable Sales
    • 6.5.3 Strengths and Weaknesses
    • 6.5.4 Recent Developments
  • 6.6 Takeda Pharmaceutical Company Ltd
    • 6.6.1 Business Overview
    • 6.6.2 Key Injectable Sales
    • 6.6.3 Strengths and Weaknesses
    • 6.6.4 Recent Developments

List of Figures:

  • Figure 3-1: Injectables Market (Million £), 2012-2017
  • Figure 3-2: Injectables Market by Player (%), 2010
  • Figure 3-3: Injectables Market by Player (%), 2012
  • Figure 6-1: Novo Nordisk - Break up of Revenue by Business Segment (%), 2012
  • Figure 6-2: Novo Nordisk - Diabetes Care Revenue by Segment (%), 2012
  • Figure 6-3: Novo Nordisk UK - Break up of Revenue by Segment (%), 2012
  • Figure 6-4: Sanofi - Break up of Revenue by Business Segment (%), 2012
  • Figure 6-5: Eli Lily & Co. - Break up of Revenue by Business Segment (%), 2012
  • Figure 6-6: Eli Lily & Co. - Human Pharmaceutical Division Revenue by Segment (%), 2012
  • Figure 6-7: Pfizer - Break up of Revenue by Business Segment (%), 2012

List of Tables:

  • Table 3-1: Top 10 Injectable Sales (Million £), 2010-2012
  • Table 3-2: Injectable Sales by Top 10 Therapeutics (Million £), 2010-2012
  • Table 6-1: Novo Nordisk UK - Key Injectable Sales (Million £), 2010-2012
  • Table 6-2: Novo Nordisk UK - Strengths and Weaknesses
  • Table 6-3: Sanofi UK - Key Injectable Sales (Million £), 2010-2012
  • Table 6-4: Sanofi UK - Strengths and Weaknesses
  • Table 6-5: Eli Lily & Co. UK - Key Injectable Sales (Million £), 2010-2012
  • Table 6-6: Eli Lily & Co. UK - Strengths and Weaknesses
  • Table 6-7: Pfizer UK - Key Injectable Sales (Million £), 2010-2012
  • Table 6-8: Pfizer UK - Strengths and Weaknesses
  • Table 6-9: Abbott Laboratories UK - Key Injectable Sales (Million £), 2010-2012
  • Table 6-10: Abbott Laboratories UK - Strengths and Weaknesses
  • Table 6-11: Takeda Pharmaceuticals UK - Key Injectable Sales (Million £), 2010-2012
  • Table 6-12: Takeda Pharmaceuticals UK - Strengths and Weaknesses
Back to Top